- Report
- April 2025
- 269 Pages
Global
From €5355EUR$5,850USD£4,551GBP
- Report
- February 2025
- 200 Pages
Global
From €4110EUR$4,490USD£3,493GBP
- Report
- April 2025
- 200 Pages
Global
From €7277EUR$7,950USD£6,185GBP
- Report
- August 2022
- 120 Pages
Global
From €4119EUR$4,500USD£3,501GBP
- Report
- December 2023
- 259 Pages
Global
€4572EUR$4,995USD£3,886GBP
- Report
- April 2025
- 50 Pages
Global
From €2426EUR$2,650USD£2,062GBP
Alosetron is a drug used to treat severe diarrhea-predominant irritable bowel syndrome (IBS-D) in women. It is a 5-HT3 receptor antagonist, meaning it blocks the action of serotonin, a neurotransmitter that can cause diarrhea. Alosetron is used to reduce the frequency and severity of abdominal pain and diarrhea associated with IBS-D. It is not recommended for use in men due to the risk of serious side effects.
The Alosetron market is composed of pharmaceutical companies that manufacture and distribute the drug. These companies are responsible for the research and development of the drug, as well as its marketing and distribution. They also provide information about the drug to healthcare professionals and patients.
Some companies in the Alosetron market include GlaxoSmithKline, Novartis, Pfizer, and Sanofi. Show Less Read more